OakChart

Journey Medical Corp

DERMHealthcare·Drug Manufacturers - Specialty & Generic·USA·Micro·NASD·Nov 11 • 3:59 PM ET

4.44+0.02 (0.45%)
2026-11-12 00:54 CET
Market cap
124.75 USD m
Revenue, TTM
68.18 USD m
Net income, TTM
-6.10 USD m
Free cash flow, TTM
-7.57 USD m
EPS diluted, TTM
-0.23
P/E
-
Compare

Price

DERM against its 20, 50 and 200-day averages
2050200beatearnings
5.006.007.008.001.1M2.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DERMclose 4.4420-day 4.8750-day 6.03200-day 6.484.4452w low

53.5% under the 52-week high of 9.56 on 23 Jan 2026. 52-week low 4.25 on 5 Nov 2026. Last 15 sessions, 28.8% high to low

Volume 0.90× normal · the line is the 50-bar volume average

Profile

DERM
52-week range, 4% of the way up
4.259.56

Journey Medical Corporation is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Employees58
IPONov 12, 2021
Beta1.17
ATR, 14d0.32
Rel volume0.90
Short float21.23%
Insider own48.50%
Inst own36.43%

Snapshot

6 groups

Valuation

Index-
Market Cap125.31M
Enterprise Value125.21M
Income-6.10M
Sales68.18M
Book/sh1.16
Cash/sh0.91
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees58
IPONov 12, 2021

Ratios

P/E-
Forward P/E10.03
PEG-
P/S1.84
P/B3.82
P/C4.89
P/FCF-
EV/EBITDA95.58
EV/Sales1.84
Quick Ratio1.41
Current Ratio1.59
Debt/Eq0.80
LT Debt/Eq0.64
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.23
EPS next Y0.44
EPS next Q-0.02
EPS this Y73.40%
EPS next Y454.00%
EPS next 5Y-
EPS past 3/5Y34.88% -
Sales past 3/5Y-5.66% 6.79%
EPS Y/Y TTM40.71%
Sales Y/Y TTM20.89%
EPS Q/Q93.01%
Sales Q/Q23.33%
EarningsNov 12 AMC
EPS/Sales Surpr.55.56% 0.82%

Ownership

Insider Own48.50%
Insider Trans0.00%
Inst Own36.43%
Inst Trans-12.58%
ROA-6.80%
ROE-23.77%
ROIC-11.61%
Gross Margin59.26%
Oper. Margin-4.41%
Profit Margin-8.95%
SMA20-8.76%
SMA50-26.37%
SMA200-31.46%
Trades-

Technical

Shs Outstand21.66M
Shs Float14.53M
Short Float21.23%
Short Ratio16.08
Short Interest3.09M
52W High9.56 -53.53%
52W Low4.25 4.47%
Volatility6.46% 6.61%
ATR (14)0.32
RSI (14)34.92
Beta1.17
Rel Volume0.90
Avg Volume191.86K
Volume172,965

Performance

Perf Week-6.13%
Perf Month-21.83%
Perf Quarter-33.23%
Perf Half Y-14.45%
Perf YTD-42.41%
Perf Year-50.94%
Perf 3Y19.03%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price13.75
Prev Close4.42
Price4.44
Change %0.45%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Aug 25, 2025InitiatedHH.C. WainwrightBuy$13+192.8%
Jul 30, 2025ResumedRB. Riley SecuritiesBuy$12+170.3%
Aug 22, 2024InitiatedRRodman & RenshawBuy$9+102.7%
Jun 28, 2024ResumedRROTH MKMBuy$11+147.7%
Dec 07, 2021InitiatedRB. Riley SecuritiesBuy$14+215.3%

Peers

Mkt cap
TickerCompanyMkt cap
BHCBausch Health Companies Inc3.13B
BFRIBiofrontera Inc13.92M
VRCAVerrica Pharmaceuticals Inc67.17M
EOLSEvolus Inc491.11M
ARQTArcutis Biotherapeutics Inc3.59B
HROWHarrow Inc1.10B
ORGOOrganogenesis Holdings Inc136.29M
SLGLSol-Gel Technologies Ltd207.57M
CPIXCumberland Pharmaceuticals Inc91.70M
DRMADermata Therapeutics Inc3.54M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B

News

latest 14 of 198

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.020--20.324
2026Q22026-08-12-0.010-0.023-0.01018.5118.364
2026Q12026-05-13-0.080-0.088-0.08215.9615.474
2025Q42026-03-25-0.040-0.053-0.04616.0818.854
2025Q32025-11-12-0.090-0.048-0.09317.6318.864
2025Q22025-08-12-0.160-0.105-0.16315.0114.794
2025Q12025-05-14-0.180-0.238-0.18013.1412.084
2024Q42025-03-260.100-0.1980.06913.6114.014
2024Q32024-11-12-0.120-0.170-0.11614.6314.395
2024Q22024-08-12-0.170-0.143-0.16814.8613.893
2024Q12024-05-13-0.530-0.235-0.52913.0314.112
2023Q42024-03-21-0.590-0.085-0.11115.2614.952
2023Q32023-11-070.990-0.1550.79834.5016.902
2023Q22023-08-08-0.040-0.335-0.46517.2014.802
2023Q12023-05-22-0.570-0.447-0.56912.2116.183
2022Q42023-03-29-0.600-0.467-0.60015.9216.573

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-4.320-2.620-2.54163.1366.01
2022FY-1.690-1.557-1.69071.0074.27
2023FY-0.210-0.175-0.21179.1878.95
2024FY-0.720-1.000-0.71856.1356.52
2025FY-0.470-0.480-0.47061.8664.65
2026FY--0.125--77.16
2027FY-0.443--115.18
2028FY-1.050--162.3
2029FY-1.420--186.89
2030FY-1.525--200.5

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-2740220.3219.1021.70
2026Q3S2026-10-2240420.3219.1021.70
2026Q3S2026-10-1341321.4219.1023.80
2026Q3S2026-09-2341321.9021.0023.80
2026Q3S2026-08-1341321.8921.0023.80
2026Q3S2026-08-1240022.4021.9223.40
2026Q3S2026-07-2840022.4021.9223.40
2026Q3S2026-06-2641222.4021.9223.40
2026Q3S2026-06-0941222.4021.9223.36
2026Q3S2026-05-1441322.4021.9223.36
2026Q3S2026-03-2640123.0421.9724.20
2026Q3S2025-11-2810029.0429.0429.04
2026Q3S2025-11-1410029.0029.0029.00
2026Q3S2025-11-1310029.0429.0429.04

Estimate history

EPS, annual0.2180.317-2.541-1.69-0.211-0.718-0.467-0.2317
Period2019202020212022202320242025TTM
EPS, quarterly-0.168-0.1160.069-0.18-0.163-0.093-0.046-0.082-0.011
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual34.92144.53163.13473.66979.18156.13461.85868.18
Period2019202020212022202320242025TTM
Sales, quarterly14.85514.62913.6213.13915.00917.63116.07915.96118.51
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual16.6616.6617.31617.76619.32422.15427.14527.657
Period2019202020212022202320242025MRQ
Shares, quarterly20.01820.72922.15423.10423.47226.37327.14527.33427.657
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue68.1861.8656.1379.1873.6763.1344.5334.92
Cost of Goods Sold Incl. D&A27.7825.1824.3026.6630.7732.0814.6010.54
Gross Profit40.4036.6831.8352.5242.8931.0529.9324.38
Selling, General and Administrative Excl. Other43.4144.8550.0651.4570.4156.3922.0819.12
Research and Development0.490.489.867.5410.9416.560.000.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.01-8.17-18.231.07-27.52-25.347.855.26
Interest Expense3.673.702.701.702.027.030.700.26
Unusual Expense0.000.00-1.123.140.009.990.000.00
Net Income Before Taxes-6.09-11.37-14.61-3.63-29.57-42.367.155.00
Income Taxes0.010.060.060.220.061.631.871.38
Consolidated Net Income-6.10-11.43-14.67-3.85-29.63-43.995.283.62
Net Income From Continuing Operations-6.10-11.43-14.67-3.85-29.63-43.995.283.62
Net Income-6.10-11.43-14.67-3.85-29.63-43.995.283.62
EPS (Recurring)-0.22-0.47-0.76-0.09-1.69-2.140.320.22
EPS (Basic, Before Extraordinaries)-0.23-0.47-0.72-0.21-1.69-2.540.320.22
EPS (Diluted)-0.23-0.47-0.72-0.21-1.69-2.540.320.22
EBITDA1.31-3.83-14.814.92-23.15-22.789.376.46
Non-Operating Income (Expense)0.590.505.190.14-0.030.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.994.974.822.063.501.800.110.18
Price To Sales Ratio2.853.051.421.330.461.48--
Gross Margin59.2659.2956.7166.3358.2349.1867.2269.83
Operating Margin-4.41-13.21-32.481.35-37.35-40.1417.6315.06
Net Margin-8.95-18.48-26.14-4.87-40.22-69.6811.8610.38
Shares Outstanding27.6627.1422.1519.3217.7717.3216.6616.66
Market Capitalization124.75124.7581.68106.5433.8788.4585.00-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue18.5115.9616.0817.6315.0113.1413.6214.63
Cost of Goods Sold Incl. D&A7.117.346.506.826.005.865.665.29
Gross Profit11.408.629.5710.819.017.287.969.34
Selling, General and Administrative Excl. Other10.9410.1110.0212.3411.8810.6110.2812.24
Research and Development0.050.000.150.290.000.040.220.84
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income0.46-1.49-0.44-1.53-2.88-3.32-2.32-2.89
Interest Expense0.910.890.930.940.940.890.830.76
Unusual Expense0.000.000.000.000.000.000.00-1.12
Net Income Before Taxes-0.30-2.23-1.25-2.31-3.74-4.071.58-2.39
Income Taxes0.010.000.000.000.060.000.060.00
Consolidated Net Income-0.31-2.23-1.25-2.31-3.80-4.071.52-2.39
Net Income From Continuing Operations-0.31-2.23-1.25-2.31-3.80-4.071.52-2.39
Net Income-0.31-2.23-1.25-2.31-3.80-4.071.52-2.39
EPS (Recurring)-0.01-0.08-0.05-0.09-0.16-0.180.07-0.15
EPS (Basic, Before Extraordinaries)-0.01-0.08-0.05-0.09-0.16-0.180.07-0.12
EPS (Diluted)-0.01-0.08-0.05-0.09-0.16-0.180.07-0.12
EBITDA1.45-0.340.65-0.44-1.79-2.24-1.34-2.06
Non-Operating Income (Expense)0.150.150.130.150.080.144.730.14
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.140.991.401.461.061.321.091.64
Price To Sales Ratio2.851.983.382.992.972.371.542.01
Gross Margin61.5853.9959.5461.3260.0055.4458.4463.87
Operating Margin2.46-9.35-2.76-8.67-19.16-25.30-17.03-19.78
Net Margin-1.69-13.97-7.76-13.13-25.29-31.0011.17-16.34
Shares Outstanding27.6627.3327.1426.3723.4723.1022.1520.73
Market Capitalization124.75155.97209.22187.33167.26123.2581.68117.11

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments24.0920.3027.4432.0049.088.254.80
Short Term Receivables29.7810.2315.2228.2123.1123.9318.95
Inventories9.6214.4310.2114.169.861.400.86
Other Current Assets3.383.213.593.312.441.660.66
Total Current Assets66.8748.1856.4577.6884.4935.2425.27
Net Property, Plant & Equipment0.110.200.100.190.090.170.09
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets27.6131.8620.2927.2012.5515.037.38
Deferred Tax Assets----0.001.451.12
Other Assets0.000.000.010.100.150.010.01
Total Assets94.5980.2476.85105.1697.2851.9133.86
Short Term Debt Incl. Current Port. of LT Debt0.100.713.105.285.424.610.08
Accounts Payable9.3116.5818.3436.9823.401.962.11
Income Tax Payable0.070.060.050.04---
Other Current Liabilities27.9617.8320.3724.5422.7921.5018.71
Total Current Liabilities37.4435.1741.8766.8351.6128.0620.90
Long Term Debt25.3025.0014.6321.353.638.234.99
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities----0.010.10-
Other Liabilities0.000.000.000.000.005.225.22
Total Liabilities62.7460.1756.5088.1855.2441.6131.11
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity31.8520.0720.3516.9842.0410.292.75
Total Shareholders Equity31.8520.0720.3516.9842.0410.292.75
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity31.8520.0720.3516.9842.0410.292.75
Total Liabilities & Stockholders Equity94.5980.2476.85105.1697.2851.9133.86
Book Value Per Share1.170.911.050.962.430.620.17
Tangible Book Value Per Share0.16-0.530.00-0.571.70-0.28-0.28
Full-Time Employees58415880908282
Price to Book Ratio3.817.426.131.292.22-7.36-
Return on Assets-13.08-18.68-4.23-29.27-58.9812.32-
Return on Equity-44.03-72.60-20.64-100.39-168.1281.00-
Return on Invested Capital-20.00-32.56-11.01-77.30-96.3328.5246.82
Quick Ratio1.530.961.100.951.451.211.17
Current Ratio1.791.371.351.161.641.261.21

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-6.10-11.43-14.67-3.85-29.63-43.995.283.62
Depreciation4.324.353.423.854.372.561.521.26
Other Funds (Non Cash)6.476.475.896.895.5422.980.900.59
Funds from Operations4.68-0.62-5.366.89-19.72-16.897.365.55
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-12.25-11.90-3.77-1.666.1914.71-2.233.46
Income Taxes Payable-0.070.010.010.020.03-0.092.191.02
Cash from Operating Activities-7.57-12.52-9.135.24-13.53-2.185.139.02
Capital Expenditures0.000.00-15.00-5.00-20.00-10.00-1.20-2.40
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.00-15.00-5.00-20.00-10.00-1.20-2.40
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock12.9216.938.294.62-0.2330.990.010.00
Repurchase of Common Pref Stock0.000.000.000.00-0.37-1.550.000.00
Sale of Common Pref Stock12.9216.938.294.620.1432.540.010.00
Proceedsfrom Stock Options12.5816.588.094.490.0032.540.000.00
Issuance or Reduction of Debt, Net0.00-0.628.70-9.4216.6822.02-0.50-3.55
Change in Long Term Debt0.000.009.95-5.4721.6827.320.000.00
Issuance of Long Term Debt0.000.009.9514.5324.7635.510.000.00
Reduction of Long Term Debt0.000.000.00-20.00-3.08-8.180.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities12.9216.3016.99-4.8016.4653.02-0.49-3.55
Net Change in Cash5.353.79-7.13-4.56-17.0840.843.443.07
Free Cash Flow-7.57-12.52-9.135.24-13.53-5.139.02
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Price to Free Cash Flow---20.04----
Deferred Taxes & Investment Tax Credit-0.000.000.000.001.57-0.340.07

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments25.6427.2224.0924.9520.2921.07
Short Term Receivables36.2524.9929.7817.9815.6418.02
Inventories8.169.299.6211.8212.8512.50
Other Current Assets2.743.463.381.642.482.40
Total Current Assets72.7864.9766.8756.3951.2753.99
Net Property, Plant & Equipment0.070.090.110.130.160.18
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets25.5126.4827.6128.6729.7330.80
Other Assets0.000.000.000.000.000.00
Total Assets98.3691.5394.5985.1981.1684.96
Short Term Debt Incl. Current Port. of LT Debt5.072.590.105.723.851.97
Accounts Payable8.058.679.3112.3113.5914.80
Income Tax Payable0.000.070.070.070.070.06
Other Current Liabilities32.6526.4927.9621.6122.9723.39
Total Current Liabilities45.7737.8337.4439.7240.4840.22
Long Term Debt20.4722.8725.3019.5821.4323.20
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities66.2460.7062.7459.2961.9163.42
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity32.1130.8331.8525.9019.2521.54
Total Shareholders Equity32.1130.8331.8525.9019.2521.54
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity32.1130.8331.8525.9019.2521.54
Total Liabilities & Stockholders Equity98.3691.5394.5985.1981.1684.96
Book Value Per Share1.161.131.170.980.820.93
Tangible Book Value Per Share0.240.160.16-0.11-0.45-0.40
Full-Time Employees--58---
Price to Book Ratio3.814.007.858.687.706.51
Return on Assets-6.80-10.86-13.08-11.61-11.94-10.96
Return on Equity-23.77-36.61-44.03-47.05-57.22-48.14
Return on Invested Capital-0.59-4.15-2.18-5.09-9.33-9.10
Quick Ratio1.411.471.531.120.951.03
Current Ratio1.591.721.791.421.271.34

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-0.31-2.23-1.25-2.31-3.80-4.07
Depreciation0.991.151.091.091.091.09
Other Funds (Non Cash)1.521.111.782.051.021.62
Funds from Operations2.210.031.620.82-1.69-1.37
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.942.88-7.98-3.210.75-1.46
Income Taxes Payable-0.070.00-0.000.000.01-0.00
Cash from Operating Activities-1.732.91-6.36-2.38-0.94-2.83
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.160.225.437.110.174.22
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.160.225.437.110.174.22
Proceedsfrom Stock Options0.000.155.427.010.004.15
Issuance or Reduction of Debt, Net0.000.000.000.000.00-0.62
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.160.225.507.040.173.60
Net Change in Cash-1.583.13-0.864.66-0.780.77
Free Cash Flow-1.732.91-6.36-2.38-0.94-2.83

Revenue breakdown

Accutane2024: 19.41M 2025: 12.88M
Emrosi2025: 14.75M
Foam franchise products Amzeeq & Zilxi2024: 6.65M 2025: 5.86M
Other (Legacy)2024: 3.96M 2025: 2.74M
Qbrexza2024: 25.11M 2025: 25.01M
United States2024: 55.13M 2025: 61.24M
Consolidation, Policy2024: -1.00M 2025: -619.00K
Dermatological2024: 56.13M 2025: 61.86M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.23%3.1M14.5M197.72K
2026-10-1520.56%3.0M14.5M187.94K
2026-09-3021.03%3.1M14.5M185.03K
2026-09-1520.15%2.9M14.5M239.88K
2026-08-3120.72%3.0M14.3M245.00K
2026-08-1421.23%2.9M13.7M260.96K
2026-07-3121.52%2.9M13.4M262.93K
2026-07-1522.84%3.1M13.4M271.29K
2026-06-3022.39%3.0M13.4M278.91K
2026-06-1525.92%3.5M13.6M270.84K
2026-05-2926.05%3.5M13.5M259.00K
2026-05-1525.71%3.5M13.5M241.60K
2026-04-3027.42%3.7M13.4M206.83K
2026-04-1527.51%3.7M13.5M204.78K
2026-03-3122.71%3.5M15.2M190.64K
2026-03-1313.53%2.6M19.5M121.63K
2026-02-2713.08%2.5M19.5M132.35K
2026-02-1313.23%2.6M19.5M137.19K
2026-01-3014.66%2.6M17.5M167.91K
2026-01-1514.23%2.5M17.5M172.07K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.604.902.3021.31355.000.000.945-0.0120.001
call5.000.004.903.1224.0495.000.000.969-0.0640.000
call7.500.000.150.152.8671970.000.171-0.0290.002
call10.000.004.900.008.2210.000.000.503-0.1240.003
call12.500.004.900.008.9930.000.000.486-0.1350.003
call15.000.004.900.009.5850.000.000.475-0.1440.003
put2.500.000.050.072.7052.000.00-0.052-0.0110.001
put5.000.001.850.405.40516.000.00-0.036-0.0710.001
put7.500.505.201.3410.66510.000.00-0.829-0.0280.002
put10.003.108.000.0013.0030.000.00-0.858-0.0320.002
put12.505.6010.500.0013.7590.000.00-0.873-0.0350.001
put15.008.0012.600.0012.7180.000.00-0.881-0.0370.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-09SCHEDULE 13G/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-31SCHEDULE 13G/ASEC
2026-07-15SCHEDULE 13G/ASEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-268-KCurrent report2026-06-24SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-04-30SCHEDULE 13GSEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-24SEC
2026-04-244Statement of changes in beneficial ownership of securities2026-04-22SEC
2026-04-244Statement of changes in beneficial ownership of securities2026-04-22SEC
2026-04-244Statement of changes in beneficial ownership of securities2026-04-22SEC
2026-04-218-KCurrent report2026-04-21SEC
2026-04-06SCHEDULE 13G/ASEC
2026-03-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-258-KCurrent report2026-03-25SEC
2026-01-23424B3SEC
2026-01-23424B3SEC
2026-01-21EFFECTEffectiveness filing by commission orderSEC
2026-01-15CORRESPSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
WASATCH ADVISORS LP8.68%
TANG CAPITAL MANAGEMENT LLC5.85%
VANGUARD CAPITAL MANAGEMENT LLC2.45%
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.1.95%
Pale Fire Capital SE1.92%
First Eagle Investment Management, LLC1.71%
Opaleye Management Inc.1.27%
Summit Financial, LLC1.26%
JANE STREET GROUP, LLC1.16%
Diametric Capital, LP1.07%

Funds

Fund% owned
Wasatch Micro Cap Fund4.42%
Wasatch Micro Cap Value Fund2.55%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.71%
Fidelity Small Cap Index Fund0.75%
VANGUARD EXTENDED MARKET INDEX FUND0.68%
VANGUARD RUSSELL 2000 INDEX FUND0.38%
Fidelity Extended Market Index Fund0.29%
iShares Micro-Cap ETF0.18%
Schwab Small-Cap Index Fund0.17%
Fidelity Total Market Index Fund0.15%

OakChart. DERM. Cached 15 minutes.

Some panels did not load: insider.